S&P 500
(1.02%) 5 099.96 points
Dow Jones
(0.40%) 38 240 points
Nasdaq
(2.03%) 15 928 points
Oil
(0.11%) $83.66
Gas
(-1.16%) $1.619
Gold
(0.30%) $2 349.60
Silver
(-0.43%) $27.52
Platinum
(0.42%) $924.40
USD/EUR
(0.32%) $0.935
USD/NOK
(0.67%) $11.02
USD/GBP
(0.13%) $0.800
USD/RUB
(-0.07%) $92.11

Echtzeitaktualisierungen für Bavarian Nordic A/S [BVNRY]

Börse: OTC Sektor: Healthcare Industrie: Biotechnology
Zuletzt aktualisiert26 Apr 2024 @ 17:20

1.82% $ 7.05

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 17:20):

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name...

Stats
Tagesvolumen 892.00
Durchschnittsvolumen 5 243.00
Marktkapitalisierung 1.65B
EPS $0 ( 2024-03-07 )
Nächstes Ertragsdatum ( $0 ) 2024-05-14
Last Dividend $0.593 ( 2020-03-27 )
Next Dividend $0 ( N/A )
P/E 7.66
ATR14 $0 (0.00%)

Bavarian Nordic A/S Korrelation

10 Am meisten positiv korreliert
10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Bavarian Nordic A/S Finanzdaten

Annual 2023
Umsatz: $7.06B
Bruttogewinn: $4.52B (64.07 %)
EPS: $19.23
FY 2023
Umsatz: $7.06B
Bruttogewinn: $4.52B (64.07 %)
EPS: $19.23
FY 2023
Umsatz: $0
Bruttogewinn: $0 (0.00 %)
EPS: $0
FY 2022
Umsatz: $3.15B
Bruttogewinn: $1.70B (53.99 %)
EPS: $-4.93

Financial Reports:

No articles found.

Bavarian Nordic A/S Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Bavarian Nordic A/S Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.34 - Potential for dividend initiation, but uncertain (13.19%)
Information
First Dividend $0.593 2020-03-27
Last Dividend $0.593 2020-03-27
Next Dividend $0 N/A
Payout Date 2020-04-06
Next Payout Date N/A
# dividends 1 --
Total Paid Out $0.593 --
Avg. Dividend % Per Year 0.00% --
Score 2.27 --
Div. Sustainability Score 10.00
Div.Growth Potential Score 4.34
Div. Directional Score 7.53 --
Next Divdend (Est)
(2024-04-28)
$0 Estimate 0.00 %
Dividend Stability
0.02 Very Bad
Dividend Score
2.27
Pay Frequency
Insufficient data to determine frequency
Yearly Payout
Year Amount Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
SWRAY Ex Dividend Knight 2023-09-12 Semi-Annually 0 0.00%
HNFSA Ex Dividend Junior 2023-08-09 Quarterly 0 0.00%
ATDRY Ex Dividend Knight 2023-08-24 Semi-Annually 0 0.00%
OSCUF Ex Dividend Junior 2023-09-28 Annually 0 0.00%
DQJCF Ex Dividend Knight 2023-12-28 Semi-Annually 0 0.00%
TSGTY Ex Dividend Knight 2023-06-23 Annually 0 0.00%
JDVB Ex Dividend Knight 2023-07-27 Quarterly 0 0.00%
BMBN Ex Dividend Knight 2023-06-30 Semi-Annually 0 0.00%
RCBC Ex Dividend Junior 2023-07-31 Quarterly 0 0.00%
FABP Ex Dividend Knight 2023-07-31 Quarterly 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.2091.5005.828.74[0 - 0.5]
returnOnAssetsTTM0.1031.2006.577.89[0 - 0.3]
returnOnEquityTTM0.1531.5009.4110.00[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM1.9380.8005.314.25[1 - 3]
quickRatioTTM1.3420.8006.815.45[0.8 - 2.5]
cashRatioTTM0.5301.5008.1710.00[0.2 - 2]
debtRatioTTM0.00430-1.5009.93-10.00[0 - 0.6]
interestCoverageTTM25.161.0001.7931.793[3 - 30]
operatingCashFlowPerShareTTM14.592.005.1410.00[0 - 30]
freeCashFlowPerShareTTM1.8492.009.0810.00[0 - 20]
debtEquityRatioTTM0.00597-1.5009.98-10.00[0 - 2.5]
grossProfitMarginTTM0.6521.0002.472.47[0.2 - 0.8]
operatingProfitMarginTTM0.2151.0007.707.70[0.1 - 0.6]
cashFlowToDebtRatioTTM18.151.00010.0010.00[0.2 - 2]
assetTurnoverTTM0.4920.800-0.0521-0.0416[0.5 - 2]
Total Score10.72

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM2.551.0009.840[1 - 100]
returnOnEquityTTM0.1532.509.6210.00[0.1 - 1.5]
freeCashFlowPerShareTTM1.8492.009.3810.00[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM14.592.005.1410.00[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM0.002281.500-3.320[0.5 - 2]
operatingCashFlowSalesRatioTTM0.1581.0008.540[0.1 - 0.5]
Total Score4.34

Bavarian Nordic A/S

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers. It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Über Live-Signale

Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.

Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.